Model-adjusted change in HbA1c from baseline to week 32 was -078 % ( 95 % CI -087 to -069 ) in the albigludite group and -099 % ( -108 to -090 ) in the liraglutide group ; treatment difference was 021 % ( 008-034 ; non-inferiority p value = 00846 ) .